» Articles » PMID: 22790873

Mcl-1 and Bcl-xL Regulate Bak/Bax-dependent Apoptosis of the Megakaryocytic Lineage at Multistages

Overview
Specialty Cell Biology
Date 2012 Jul 14
PMID 22790873
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Anti-apoptotic Bcl-2 family proteins, which inhibit the mitochondrial pathway of apoptosis, are involved in the survival of various hematopoietic lineages and are often dysregulated in hematopoietic malignancies. However, their involvement in the megakaryocytic lineage is not well understood. In the present paper, we describe the crucial anti-apoptotic role of Mcl-1 and Bcl-xL in this lineage at multistages. The megakaryocytic lineage-specific deletion of both, in sharp contrast to only one of them, caused apoptotic loss of mature megakaryocytes in the fetal liver and systemic hemorrhage, leading to embryonic lethality. ABT-737, a Bcl-xL/Bcl-2/Bcl-w inhibitor, only caused thrombocytopenia in adult wild-type mice, but further induced massive mature megakaryocyte apoptosis in the Mcl-1 knockout mice, leading to severe hemorrhagic anemia. All these phenotypes were fully restored if Bak and Bax, downstream apoptosis executioners, were also deficient. In-vitro study revealed that the Jak pathway maintained Mcl-1 and Bcl-xL expression levels, preventing megakaryoblastic cell apoptosis. Similarly, both were involved in reticulated platelet survival, whereas platelet survival was dependent on Bcl-xL due to rapid proteasomal degradation of Mcl-1. In conclusion, Mcl-1 and Bcl-xL regulate the survival of the megakaryocytic lineage, which is critically important for preventing lethal or severe hemorrhage in both developing and adult mice.

Citing Articles

Apoptotic cell death in disease-Current understanding of the NCCD 2023.

Vitale I, Pietrocola F, Guilbaud E, Aaronson S, Abrams J, Adam D Cell Death Differ. 2023; 30(5):1097-1154.

PMID: 37100955 PMC: 10130819. DOI: 10.1038/s41418-023-01153-w.


Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms.

da Costa Cacemiro M, Cominal J, Pereira L, Berzoti-Coelho M, Berbel G, Baroni L Med Oncol. 2022; 39(5):97.

PMID: 35599283 DOI: 10.1007/s12032-022-01696-x.


What can we learn from mice lacking pro-survival BCL-2 proteins to advance BH3 mimetic drugs for cancer therapy?.

Brinkmann K, Ng A, de Graaf C, Strasser A Cell Death Differ. 2022; 29(6):1079-1093.

PMID: 35388168 PMC: 9177562. DOI: 10.1038/s41418-022-00987-0.


DMAG, a novel countermeasure for the treatment of thrombocytopenia.

Lin J, Zeng J, Liu S, Shen X, Jiang N, Wu Y Mol Med. 2021; 27(1):149.

PMID: 34837956 PMC: 8626956. DOI: 10.1186/s10020-021-00404-1.


The multiple mechanisms of MCL1 in the regulation of cell fate.

Widden H, Placzek W Commun Biol. 2021; 4(1):1029.

PMID: 34475520 PMC: 8413315. DOI: 10.1038/s42003-021-02564-6.


References
1.
Xing S, Wanting T, Zhao W, Ma J, Wang S, Xu X . Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008; 111(10):5109-17. PMC: 2384138. DOI: 10.1182/blood-2007-05-091579. View

2.
Kaushansky K . The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005; 115(12):3339-47. PMC: 1297257. DOI: 10.1172/JCI26674. View

3.
Steimer D, Boyd K, Takeuchi O, Fisher J, Zambetti G, Opferman J . Selective roles for antiapoptotic MCL-1 during granulocyte development and macrophage effector function. Blood. 2008; 113(12):2805-15. PMC: 2661864. DOI: 10.1182/blood-2008-05-159145. View

4.
Motoyama N, Wang F, Roth K, Sawa H, Nakayama K, Negishi I . Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science. 1995; 267(5203):1506-10. DOI: 10.1126/science.7878471. View

5.
Aichberger K, Mayerhofer M, Gleixner K, Krauth M, Gruze A, Pickl W . Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood. 2006; 109(7):3031-41. DOI: 10.1182/blood-2006-07-032714. View